Trial 11S-15-1


SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Biological Response Modifier
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  James Hu, M.D.
Other Trial Staff:  Cheryl Kefauver, R.N., Victoria Amran, D.M., Lagrimas Ilagan, D.M., Honorina Enright, D.M., Laurie De Oliveira, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.